Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 157

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 157
---
 each Series F Warrant exercised.

The
Replacement Warrants were exercisable immediately and expire after five years, for the Series G Warrants, and one year, for the Series
H Warrants, from the date of issuance. The registration statement of which this prospectus forms a part includes the Ordinary Shares (represented
by Depositary Shares) issuable upon exercise of the Replacement Warrants, as well as the Ordinary Shares (represented by Depositary Shares)
received upon exercise of the Series E Warrants and Series F Warrants.

| 79 |

Ladenburg, acted
as warrant inducement agent and financial advisor in connection with the transaction and received a cash fee of 8.0% of the gross proceeds
and reimbursement of certain expenses. We also issued to Ladenburg and certain designees of Ladenburg Warrants Agent Warrants for purchase
of an aggregate of 6,456 Depositary Shares at an exercise price of $62.50. The registration statement of which this forms a part includes
the Depositary Shares issuable upon exercise of these warrants.

We
received gross proceeds of approximately $6.05 million from the warrant exercise, prior to deducting the warrant inducement agent fees
and other expenses.

License and Collaboration Agreement

On
April 25, 2024, we entered into the Emtora License Agreement with Emtora, relating to the license of eRapa, an oral product formulation
of rapamycin (sirolimus), for use in the prevention, treatment, diagnosis, detection, monitoring and/or predisposition testing of all
diseases, states or conditions in humans, that includes the nanoparticle and enteric coated finished pharmaceutical formulations developed
at any time by Emtora and its affiliates. Under the License, we obtained from Emtora an exclusive, worldwide, sublicensable right to develop,
manufacture, commercialize, or otherwise exploit products containing rapamycin (sirolimus) in the Field. Pursuant to the terms of the
License Agreement, the Company and Emtora established a joint development committee, consisting of two designees of the Company and two
designees of Emtora.

As
consideration for the License, we made an upfront payment to Emtora in the form of 378,163 of our Depositary Shares (equal to five percent
(5%) of our outstanding Ordinary Shares, calculated on a fully-diluted basis (including in-the-money warrants)). In addition, we are also